KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to 20.56%.

  • Halozyme Therapeutics' EBITDA Margin fell 794500.0% to 20.56% in Q4 2025 from the same period last year, while for Dec 2025 it was 33.58%, marking a year-over-year decrease of 207300.0%. This contributed to the annual value of 33.58% for FY2025, which is 207300.0% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported EBITDA Margin of 20.56% as of Q4 2025, which was down 794500.0% from 61.51% recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' EBITDA Margin peaked at 68.19% during Q2 2021, and registered a low of 20.56% during Q4 2025.
  • Over the past 5 years, Halozyme Therapeutics' median EBITDA Margin value was 52.06% (recorded in 2024), while the average stood at 47.27%.
  • Per our database at Business Quant, Halozyme Therapeutics' EBITDA Margin soared by 697000bps in 2021 and then plummeted by -794500bps in 2025.
  • Over the past 5 years, Halozyme Therapeutics' EBITDA Margin (Quarter) stood at 55.42% in 2021, then dropped by -26bps to 41.05% in 2022, then increased by 7bps to 43.92% in 2023, then soared by 34bps to 58.89% in 2024, then plummeted by -135bps to 20.56% in 2025.
  • Its last three reported values are 20.56% in Q4 2025, 61.51% for Q3 2025, and 62.15% during Q2 2025.